OptiBiotix has published a third human volunteer study on the cholesterol lowering effects of the company's proprietary probiotic Lactobacilus plantarum, branded as LPLDL. We believe the study clearly demonstrates the cholesterol lowering effect of LPLDL which we expect to support the on-going commercialisation of the probiotic. Key results were the statistically significant reduction in total cholesterol and LDL (bad) cholesterol of 34.2% and 28.4%, respectively over a six-week treatment period ....
20 Jan 2022
Cenkos: OptiBiotix Health Plc -- Cholesterol lowering study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: OptiBiotix Health Plc -- Cholesterol lowering study
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
20 Jan 2022 -
Author:
Chris Donnellan -
Pages:
11
OptiBiotix has published a third human volunteer study on the cholesterol lowering effects of the company's proprietary probiotic Lactobacilus plantarum, branded as LPLDL. We believe the study clearly demonstrates the cholesterol lowering effect of LPLDL which we expect to support the on-going commercialisation of the probiotic. Key results were the statistically significant reduction in total cholesterol and LDL (bad) cholesterol of 34.2% and 28.4%, respectively over a six-week treatment period ....